KRAS and familial pancreatic carcinoma: In the heterogenous mutational landscape of pancreatic cancer, KRAS, TP53, SMAD4, and CDKN2A represent major oncogenic events involved in key molecular pathways such as DNA damage repair, cell cycle regulation, TGF-β signaling, chromatin regulation, and axonal guidance [8].